De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

• Published in: Science (American Association for the Advancement of Science) Vol. 370; no. 6515; pp. 426 - 431
• Main Authors: Cao, Longxing, Goreshnik, Inna, Coventry, Brian, Case, James Brett, Miller, Lauren, Kozodoy, Lisa, Chen, Rita E., Carter, Lauren, Walls, Alexandra C., Park, Young-Jun, Strauch, Eva-Maria, Stewart, Lance, Diamond, Michael S., Veesler, David, Baker, David
• Format: Journal Article
• Language: English
• Published: United States The American Association for the Advancement of Science 23.10.2020; American Association for the Advancement of Science
• Subjects: ACE2; Affinity; Amino Acid Sequence; Amino acids; Anatomy; Angiotensin; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents - chemistry; Betacoronavirus - drug effects; Binding; Binding Sites; Biochem; Cell size; Chlorocebus aethiops; Computer applications; Coronaviridae; Coronavirus Infections; Coronaviruses; COVID-19; Cryoelectron Microscopy; Design; Drug Design; Electron microscopy; Enzymes; Immunotherapy; Inhibitors; Mammalian cells; Mammals; Mathematical models; Microscopy; Molec Biol; Molecular Docking Simulation; Monoclonal antibodies; Pandemics; Peptidyl-dipeptidase A; Peptidyl-Dipeptidase A - chemistry; Pneumonia, Viral; Protein Binding - drug effects; Proteins; Receptors; Respiratory diseases; Respiratory system; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - antagonists & inhibitors; Spike Glycoprotein, Coronavirus - chemistry; Spike protein; Stability; Trimers; Vero Cells; Viral diseases

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is decorated with spikes, and viral entry into cells is initiated when these spikes bind to the host angiotensin-converting enzyme 2 (ACE2) receptor. Many monoclonal antibody therapies in development target the spike proteins. Cao et al. d...